Jeffrey Casberg discusses key upcoming biosimilars and specialty drugs, the impact of the Inflation Reduction Act on drug pricing, and the evolving role of pharmacy benefit managers in the market.
For lecanemab, scientists at AAIC highlighted the promise of the fluid tau marker MTBR-243 to track tangle load, and they ...
Modeling suggests monthly maintenance dosing will keep biomarkers flat. Several talks showed how fluid biomarkers rebound after patients stop taking the drug. Likewise, cognitive decline returned to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results